Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.85 |
| ▸ | P2RY1 | P47900 | 10/20 | 0.76 |
| ▸ | P2RY11 | Q96G91 | 5/20 | 0.76 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.76 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.76 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.76 |
| ▸ | LDHA | P00338 | 1/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.76 |
| ▸ | FBP1 | P09467 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.76 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.76 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL17541855 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL1650192 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL21173132 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL13046080 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL3511 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL23884975 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL8401646 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL899922 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL482449 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 | |
| Fludarabine Phosphate SCHEMBL14565620 | 0.92 | CA5A (1.00) | CA5AP2RY1P2RY11DNPH1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148207-B2 | For therapy of cancer; quick release tablet of fludarabine phosphate in a defined composition of residual contaminants | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-12-12 | — | — | US | claimed |
| EP-1455760-B1 | ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE | SCHERING AG (DE) | 2005-09-07 | — | — | EP | claimed |
| EP-2432457-A1 | STABLE PHARMACEUTICAL COMPOSITION OF FLUDARABINE PHOSPHATE | Grindeks, A Joint Stock Company (LV) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133629-A1 | STABLE PHARMACEUTICAL COMPOSITION OF FLUDARABINE PHOSPHATE | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2010-11-25 | — | — | WO | disclosed |
| US-7148207-B2 | For therapy of cancer; quick release tablet of fludarabine phosphate in a defined composition of residual contaminants | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1455760-B1 | ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE | SCHERING AG (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030176391-A1 | Oral fludara of high-purity formulation with quick release of active ingredient | SCHERING AG (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176391-A1 | Oral fludara of high-purity formulation with quick release of active ingredient | CYP2C19, FCGR2A, CYP2C9 | CA5A 2336/4885P2RY1 16/4885P2RY11 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.